@isabellemahe.bsky.social
How do you manage oral anticoagulants in patients undergoing an invasive dental procedure?
Our prospective national study suggests a short DOAC discontinuation before the invasive dental procedure can minimize bleeding!
@RPTHjournal
doi.org/10.1016/j.rp...
Our prospective national study suggests a short DOAC discontinuation before the invasive dental procedure can minimize bleeding!
@RPTHjournal
doi.org/10.1016/j.rp...
May 24, 2025 at 11:41 AM
How do you manage oral anticoagulants in patients undergoing an invasive dental procedure?
Our prospective national study suggests a short DOAC discontinuation before the invasive dental procedure can minimize bleeding!
@RPTHjournal
doi.org/10.1016/j.rp...
Our prospective national study suggests a short DOAC discontinuation before the invasive dental procedure can minimize bleeding!
@RPTHjournal
doi.org/10.1016/j.rp...
May 23, 2025 at 4:53 PM
How do you manage oral anticoagulants in patients undergoing an invasive dental procedure?
Our prospective national study suggests a short DOAC discontinuation before the invasive dental procedure can minimize bleeding!
@RPTHjournal
doi.org/10.1016/j.rp...
Our prospective national study suggests a short DOAC discontinuation before the invasive dental procedure can minimize bleeding!
@RPTHjournal
doi.org/10.1016/j.rp...
Reposted
Extended anticoagulant therapy with reduced-dose apixaban was noninferior to full-dose in patients with active cancer and #cvVTE, based on findings from the API-CAT trial presented at #ACC25.
Read the journal scan to learn more: bit.ly/43w2A8v
#CardioSky #MedSky
Read the journal scan to learn more: bit.ly/43w2A8v
#CardioSky #MedSky
March 29, 2025 at 4:28 PM
Extended anticoagulant therapy with reduced-dose apixaban was noninferior to full-dose in patients with active cancer and #cvVTE, based on findings from the API-CAT trial presented at #ACC25.
Read the journal scan to learn more: bit.ly/43w2A8v
#CardioSky #MedSky
Read the journal scan to learn more: bit.ly/43w2A8v
#CardioSky #MedSky
Reposted
In the API-CAT trial involving patients with active cancer and venous thromboembolism, extended anticoagulation with reduced-dose apixaban was noninferior to full-dose apixaban for preventing recurrent thromboembolic events. Full results: nej.md/41YkRZK
#ACC25 | @accintouch.bsky.social
#ACC25 | @accintouch.bsky.social
March 29, 2025 at 2:35 PM
In the API-CAT trial involving patients with active cancer and venous thromboembolism, extended anticoagulation with reduced-dose apixaban was noninferior to full-dose apixaban for preventing recurrent thromboembolic events. Full results: nej.md/41YkRZK
#ACC25 | @accintouch.bsky.social
#ACC25 | @accintouch.bsky.social
Reposted
In the API-CAT trial involving patients with active cancer and venous thromboembolism, extended anticoagulation with reduced-dose apixaban was noninferior to full-dose apixaban for preventing recurrent thromboembolic events. Full trial results and Research Summary: nej.md/41YkRZK
#MedSky
#MedSky
April 13, 2025 at 8:00 PM
In the API-CAT trial involving patients with active cancer and venous thromboembolism, extended anticoagulation with reduced-dose apixaban was noninferior to full-dose apixaban for preventing recurrent thromboembolic events. Full trial results and Research Summary: nej.md/41YkRZK
#MedSky
#MedSky
Patients with cancer and VTE are at risk for VTE recurrence, and there are limited data on appropriate and effective anticoagulation regimens beyond 6 months. Findings from the API-CAT trial are summarized in a short video.
Reduced-Dose Apixaban for Cancer-Associated VTE (API-CAT Trial) | NEJM
Patients with cancer and VTE are at risk for VTE recurrence, and there are limited data on appropriate and effective anticoagulation regimens beyond 6 months...
youtu.be
April 14, 2025 at 4:53 PM
Reposted
Patients with cancer and VTE are at risk for VTE recurrence, and there are limited data on appropriate and effective anticoagulation regimens beyond 6 months. Findings from the API-CAT trial are summarized in a short video.
Reduced-Dose Apixaban for Cancer-Associated VTE (API-CAT Trial) | NEJM
Patients with cancer and VTE are at risk for VTE recurrence, and there are limited data on appropriate and effective anticoagulation regimens beyond 6 months...
youtu.be
April 12, 2025 at 7:00 PM
Patients with cancer and VTE are at risk for VTE recurrence, and there are limited data on appropriate and effective anticoagulation regimens beyond 6 months. Findings from the API-CAT trial are summarized in a short video.
April 14, 2025 at 4:50 PM
Reposted
#APICAT trial at #ACC25 #LBCT #cardioonc
🩸apixaban low 2.5 mg vs full dose 5mg in patients with cancer+VTE: primary endpoint recurrent VTE
🩸more than half female! 👏🏽👏🏽
🩸the low dose was significant for noninferiority for efficacy & ⤵️ bleed
🩸no increase in deaths
🩸apixaban low 2.5 mg vs full dose 5mg in patients with cancer+VTE: primary endpoint recurrent VTE
🩸more than half female! 👏🏽👏🏽
🩸the low dose was significant for noninferiority for efficacy & ⤵️ bleed
🩸no increase in deaths
March 29, 2025 at 3:34 PM
#APICAT trial at #ACC25 #LBCT #cardioonc
🩸apixaban low 2.5 mg vs full dose 5mg in patients with cancer+VTE: primary endpoint recurrent VTE
🩸more than half female! 👏🏽👏🏽
🩸the low dose was significant for noninferiority for efficacy & ⤵️ bleed
🩸no increase in deaths
🩸apixaban low 2.5 mg vs full dose 5mg in patients with cancer+VTE: primary endpoint recurrent VTE
🩸more than half female! 👏🏽👏🏽
🩸the low dose was significant for noninferiority for efficacy & ⤵️ bleed
🩸no increase in deaths
Reposted
Une étude majeure dans la prise en charge des patients atteints de cancer et traités pour un événement thromboembolique veineux, deuxième cause de décès, a été menée et coordonnée par la Pr Isabelle Mahé, cheffe du service de médecine interne de @hoplouismourier.bsky.social
A découvrir ici 👇
A découvrir ici 👇
🔬 Pour la première fois, une étude démontre que la dose réduite d'un anticoagulant oral est aussi efficace que la dose pleine et réduit le risque hémorragique de 25% pour les patients atteints de #cancer traités pour thrombose veineuse ou embolie pulmonaire
Découvrez les résultats 👉 swll.to/sOSmEZC
Découvrez les résultats 👉 swll.to/sOSmEZC
April 1, 2025 at 8:14 AM
Une étude majeure dans la prise en charge des patients atteints de cancer et traités pour un événement thromboembolique veineux, deuxième cause de décès, a été menée et coordonnée par la Pr Isabelle Mahé, cheffe du service de médecine interne de @hoplouismourier.bsky.social
A découvrir ici 👇
A découvrir ici 👇
Reposted
🔬 Pour la première fois, une étude démontre que la dose réduite d'un anticoagulant oral est aussi efficace que la dose pleine et réduit le risque hémorragique de 25% pour les patients atteints de #cancer traités pour thrombose veineuse ou embolie pulmonaire
Découvrez les résultats 👉 swll.to/sOSmEZC
Découvrez les résultats 👉 swll.to/sOSmEZC
March 31, 2025 at 6:11 AM
🔬 Pour la première fois, une étude démontre que la dose réduite d'un anticoagulant oral est aussi efficace que la dose pleine et réduit le risque hémorragique de 25% pour les patients atteints de #cancer traités pour thrombose veineuse ou embolie pulmonaire
Découvrez les résultats 👉 swll.to/sOSmEZC
Découvrez les résultats 👉 swll.to/sOSmEZC
Reposted
@acc25.bsky.social Isabelle Mahe presents API-CAT
Low dose Apixaban noninferior to high dose for recurrent VTE and superior for lower bleeding-another win!
Low dose Apixaban noninferior to high dose for recurrent VTE and superior for lower bleeding-another win!
March 29, 2025 at 3:34 PM
@acc25.bsky.social Isabelle Mahe presents API-CAT
Low dose Apixaban noninferior to high dose for recurrent VTE and superior for lower bleeding-another win!
Low dose Apixaban noninferior to high dose for recurrent VTE and superior for lower bleeding-another win!
Reposted
Dr. Isabelle Mahe on the extended anticoagulant treatment with a reduced versus full dose #apixaban in patients with cancer-associated #VTE
#ACC25 #JACCJournals #APICAT #CardioOnc #cvCoag #CardioSky
#ACC25 #JACCJournals #APICAT #CardioOnc #cvCoag #CardioSky
March 29, 2025 at 3:29 PM
Dr. Isabelle Mahe on the extended anticoagulant treatment with a reduced versus full dose #apixaban in patients with cancer-associated #VTE
#ACC25 #JACCJournals #APICAT #CardioOnc #cvCoag #CardioSky
#ACC25 #JACCJournals #APICAT #CardioOnc #cvCoag #CardioSky
Reposted
Finally! More data to add to the EVE trial
APICAT showed non inferiority of apixaban 2.5BD in patients with CAVTE who have completed 6m anticoagulation to 5BD in terms of VTE recurrence (2.1% v 2.8%) and lower clinically relevant bleeding (12.1% v 15.6%)
#Hemesky #BSH
www.nejm.org/doi/full/10....
APICAT showed non inferiority of apixaban 2.5BD in patients with CAVTE who have completed 6m anticoagulation to 5BD in terms of VTE recurrence (2.1% v 2.8%) and lower clinically relevant bleeding (12.1% v 15.6%)
#Hemesky #BSH
www.nejm.org/doi/full/10....
Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism | NEJM
In patients with active cancer and venous thromboembolism, whether extended treatment
with a reduced dose of an oral anticoagulant is effective in preventing recurrent
thromboembolic events and dec...
www.nejm.org
March 30, 2025 at 8:13 PM
Finally! More data to add to the EVE trial
APICAT showed non inferiority of apixaban 2.5BD in patients with CAVTE who have completed 6m anticoagulation to 5BD in terms of VTE recurrence (2.1% v 2.8%) and lower clinically relevant bleeding (12.1% v 15.6%)
#Hemesky #BSH
www.nejm.org/doi/full/10....
APICAT showed non inferiority of apixaban 2.5BD in patients with CAVTE who have completed 6m anticoagulation to 5BD in terms of VTE recurrence (2.1% v 2.8%) and lower clinically relevant bleeding (12.1% v 15.6%)
#Hemesky #BSH
www.nejm.org/doi/full/10....
The article published in the @NEJM.org can be accessed.see below
Citation:
Mahé I, Carrier M, Didier M, et al. Extended reduced-dose apixaban for cancer-associated venous thromboembolism. NEJM. Published online March 29, 2025. Doi: 10.1056/NEJMoa2416112
Citation:
Mahé I, Carrier M, Didier M, et al. Extended reduced-dose apixaban for cancer-associated venous thromboembolism. NEJM. Published online March 29, 2025. Doi: 10.1056/NEJMoa2416112
April 1, 2025 at 9:53 PM
The article published in the @NEJM.org can be accessed.see below
Citation:
Mahé I, Carrier M, Didier M, et al. Extended reduced-dose apixaban for cancer-associated venous thromboembolism. NEJM. Published online March 29, 2025. Doi: 10.1056/NEJMoa2416112
Citation:
Mahé I, Carrier M, Didier M, et al. Extended reduced-dose apixaban for cancer-associated venous thromboembolism. NEJM. Published online March 29, 2025. Doi: 10.1056/NEJMoa2416112
April 1, 2025 at 2:35 PM
The article published in the @NEJM.org can be accessed.see below
Citation:
Mahé I, Carrier M, Didier M, et al. Extended reduced-dose apixaban for cancer-associated venous thromboembolism. NEJM. Published online March 29, 2025. Doi: 10.1056/NEJMoa2416112
Citation:
Mahé I, Carrier M, Didier M, et al. Extended reduced-dose apixaban for cancer-associated venous thromboembolism. NEJM. Published online March 29, 2025. Doi: 10.1056/NEJMoa2416112
Reposted
Prof. @isabellemahe.bsky.social presents API-CAT at @accintouch.bsky.social published in @nejm.org: Extended anticoagulation with reduced-dose apixaban is noninferior to full-dose for preventing recurrent VTE, with less clinically relevant bleeding 🩸in cancer patients
www.nejm.org/doi/full/10....
www.nejm.org/doi/full/10....
March 29, 2025 at 2:32 PM
Prof. @isabellemahe.bsky.social presents API-CAT at @accintouch.bsky.social published in @nejm.org: Extended anticoagulation with reduced-dose apixaban is noninferior to full-dose for preventing recurrent VTE, with less clinically relevant bleeding 🩸in cancer patients
www.nejm.org/doi/full/10....
www.nejm.org/doi/full/10....
Reposted
Regulatory agencies have issued warnings about JAK inhibitors and VTE risk—but what does the evidence actually say?
Our latest review breaks down the data, limitations, and next steps.
@davidmsmadja.bsky.social @isabellemahe.bsky.social
📑 Read now: buff.ly/4ijJQNq
Our latest review breaks down the data, limitations, and next steps.
@davidmsmadja.bsky.social @isabellemahe.bsky.social
📑 Read now: buff.ly/4ijJQNq
March 2, 2025 at 8:55 AM
Regulatory agencies have issued warnings about JAK inhibitors and VTE risk—but what does the evidence actually say?
Our latest review breaks down the data, limitations, and next steps.
@davidmsmadja.bsky.social @isabellemahe.bsky.social
📑 Read now: buff.ly/4ijJQNq
Our latest review breaks down the data, limitations, and next steps.
@davidmsmadja.bsky.social @isabellemahe.bsky.social
📑 Read now: buff.ly/4ijJQNq
The #VTE risk associated with #JAKi in #inflammatory diseases has been suggested, followed by precautionary measures by health authorities. This literature review illustrates that available data on VTE risk on JAKi are conflicting and inconclusive
@DavidMSmadja @RPTHjournal
doi.org/10.1016/j.rp...
@DavidMSmadja @RPTHjournal
doi.org/10.1016/j.rp...
February 26, 2025 at 12:28 PM
The #VTE risk associated with #JAKi in #inflammatory diseases has been suggested, followed by precautionary measures by health authorities. This literature review illustrates that available data on VTE risk on JAKi are conflicting and inconclusive
@DavidMSmadja @RPTHjournal
doi.org/10.1016/j.rp...
@DavidMSmadja @RPTHjournal
doi.org/10.1016/j.rp...